| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
73,550,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axcella Health is a clinical-stage biotechnology company focused on an approach to treat diseases using compositions of endogenous metabolic modulators. Co.'s pipeline includes main therapeutic candidates for the treatment of non-alcoholic steatohepatitis (NASH), for the treatment of Long COVID associated fatigue, and for the reduction in risk of recurrent overt hepatic encephalopathy (OHE). AXA1125 is being developed as an oral product candidate for the treatment of NASH. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1665 is being developed as a product candidate for the reduction in risk of OHE recurrence in adult patients with liver cirrhosis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
14,042,296 |
| Total Buy Value |
$0 |
$0 |
$0 |
$23,029,365 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
23,037 |
| Total Sell Value |
$0 |
$0 |
$0 |
$31,432 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
5 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Koziel Margaret |
Chief Medical Officer |
• – – |
2023-03-01 |
4 |
AS |
$0.58 |
$394 |
D/D |
(679) |
24,883 |
|
- |
|
| Fehlner Paul |
SVP & Chief Legal Officer |
• – – |
2023-02-10 |
4 |
S |
$0.66 |
$3,447 |
D/D |
(5,221) |
58,081 |
|
- |
|
| Hinshaw William |
President & CEO |
• • – |
2022-10-19 |
4 |
S |
$1.56 |
$25,027 |
D/D |
(16,000) |
82,012 |
|
- |
|
| Hinshaw William |
President & CEO |
• • – |
2022-10-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
98,012 |
|
- |
|
| Fpa, L.p. |
10% Owner |
– – • |
2022-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,048,780 |
|
- |
|
| Afeyan Noubar |
10% Owner |
– – • |
2022-10-13 |
4 |
B |
$1.64 |
$17,029,366 |
I/I |
10,383,760 |
3,048,780 |
1.5 |
- |
|
| Nestle Sa |
10% Owner |
– – • |
2022-10-13 |
4 |
B |
$1.64 |
$5,999,999 |
I/I |
3,658,536 |
11,105,438 |
1.5 |
- |
|
| Koziel Margaret |
Chief Medical Officer |
• – – |
2022-09-06 |
4 |
S |
$2.52 |
$1,378 |
D/D |
(547) |
25,562 |
|
- |
|
| Koziel Margaret |
Chief Medical Officer |
• – – |
2022-06-01 |
4 |
S |
$2.01 |
$1,186 |
D/D |
(590) |
26,109 |
|
- |
|
| Epstein David R |
Director |
– • – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
47,059 |
209,756 |
|
- |
|
| Epstein David R |
Director |
– • – |
2022-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,535 |
162,697 |
|
- |
|
| Epstein David R |
Director |
– • – |
2022-03-16 |
4 |
B |
$1.91 |
$50,000 |
D/D |
26,178 |
161,162 |
2.39 |
- |
|
| Afeyan Noubar |
10% Owner |
– – • |
2022-03-16 |
4 |
B |
$1.91 |
$12,069,999 |
I/I |
6,319,371 |
4,465,866 |
1.5 |
- |
|
| Fehlner Paul |
SVP & Chief Legal Officer |
• – – |
2022-03-16 |
4 |
B |
$1.91 |
$20,000 |
D/D |
10,471 |
20,802 |
2.74 |
- |
|
| Crane Robert |
Chief Financial Officer |
• – – |
2022-03-16 |
4 |
B |
$1.91 |
$75,000 |
D/D |
39,267 |
39,267 |
2.74 |
- |
|
| Hinshaw William |
President & CEO |
• • – |
2022-03-16 |
4 |
B |
$1.91 |
$25,000 |
D/D |
13,089 |
48,012 |
2.81 |
- |
|
| Nestle Sa |
10% Owner |
– – • |
2022-03-16 |
4 |
B |
$1.91 |
$6,000,000 |
I/I |
3,141,361 |
7,446,902 |
1.5 |
- |
|
| Koziel Margaret |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
S |
$1.86 |
$1,030 |
D/D |
(553) |
26,699 |
|
- |
|
| Epstein David R |
Director |
– • – |
2022-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,534 |
134,984 |
|
- |
|
| Hinshaw William |
President and CEO |
• • – |
2022-01-31 |
4 |
S |
$1.65 |
$27,393 |
D/D |
(16,590) |
33,410 |
|
- |
|
| Hinshaw William |
President and CEO |
• • – |
2022-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Epstein David R |
Director |
– • – |
2022-01-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,535 |
133,450 |
|
- |
|
| Epstein David R |
Director |
– • – |
2021-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,535 |
131,915 |
|
- |
|
| Koziel Margaret |
Chief Medical OfficerOfficer |
• – – |
2021-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000 |
|
- |
|
| Epstein David R |
Director |
– • – |
2021-11-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,534 |
130,380 |
|
- |
|
61 Records found
|
|
Page 1 of 3 |
|
|
